diclofenac potassium


Also found in: Dictionary, Medical, Wikipedia.
Related to diclofenac potassium: diclofenac sodium
Graphic Thesaurus  🔍
Display ON
Animation ON
Legend
Synonym
Antonym
Related
  • noun

Synonyms for diclofenac potassium

a nonsteroidal anti-inflammatory drug (trade name Cataflam)

References in periodicals archive ?
3 TABLE 6: Diclofenac potassium dose administration in the postoperative period PARAMETER GROUP C GROUP D GROUP DEX Dosage 75 [+ or -] 0.
Key Words: Clinical Trial Diclofenac Potassium Diclofenac Sodium.
89 It is also available with the potassium salt as diclofenac potassium also in 50 mg oral tablets.
The drug concentration levels and pharmacokinetics of orally administered diclofenac sodium and diclofenac potassium were changed during fever.
Tenders are invited for Each Tab Cap Contains Trypsin Chymotrypsin 50000 Iu Plus Diclofenac Potassium 50 Mg In Strip/ Blister Pack Only.
Tenders are invited for Diclofenac Potassium 50 Mg Tablet
PRO-513 is a patented formulation of diclofenac potassium powder for oral solution, which utilizes a unique, Dynamic Buffering Technology (DBT[TM]) that has been demonstrated to enhance the pharmacokinetic profile of diclofenac.
Tenders are invited for Injection Diclofenac Potassium 75 Mg/Ml For Im/Iv Use/Aqua Technology
PRO-513, a proprietary formulation of diclofenac potassium powder for oral solution, achieved statistical superiority to placebo in pain relief and nausea, photophobia and phonophobia at two hours for all conditions.
In an eight month randomized, double-blind, placebo-controlled trial that enrolled 690 adult patients, PRO-513, a proprietary formulation of diclofenac potassium powder for oral solution, reached all of its primary endpoints by achieving statistical superiority to placebo in pain relief (p > 0.
PRO-571 is a unique, rapid-release formulation of diclofenac potassium in tablet form, which utilizes ProEthic's Dynamic Buffering Technology (DBT).
PRO-513 is a formulation of diclofenac potassium powder for oral solution, which utilizes a unique, patented Dynamic Buffering Technology (DBT) that has been demonstrated to enhance the pharmacokinetic profile of diclofenac.
announced today that APR has granted an exclusive license to ProEthic to develop and market two fast-acting formulations of diclofenac potassium in the U.
Nasdaq:TEVIY) announced that it has received approval from the Food and Drug Administration (FDA) to manufacture and market Diclofenac Potassium 50mg tablets.